This study investigated the use of GATA binding factor 1 as a marker for neoplastic cells of pure erythroleukemia and acute megakaryoblastic leukemia.American Journal of Clinical Pathology
Authors: Zhao Y, Zhong L, Liu L, Yao SF, Chen M, Li LW, Shan ZL, Xiao CL, Gan LG, Xu T, Liu BZ
At present, acute promyelocytic leukemia (APL) is the most curable form of acute myeloid leukemia and can be treated using all-trans retinoic acid and arsenic trioxide. However, the current treatment of APL is associated with some issues such as drug toxicity, resistance and relapse. Therefore, other strategies are necessary for APL treatment. In the present study, we investigated the effects of salinomycin (SAL) on APL cell lines NB4 and HL-60 and determined its possible mechanisms. We observed that SAL inhibite…
Authors: Trussardi Fayh AP, de Carvalho Gomes C, Schroeder HT, Henrique de Lemos Muller C, Maria de Araújo Moura Lemos T, Krause M
Background: Acute lymphoblastic leukemia (ALL) is associated with higher levels of pro-inflammatory cytokines and oxidative stress. Recently, the levels of extracellular heat shock protein 72 (eHSP72) were found to be elevated in ALL, and its elevation associated with poor prognosis. Therefore, considering the possible role of eHSP72 as a modulator of the immunological system and metabolism, the aim of this study was to describe the response of eHSP72 to the induction ph…
Conclusion: Together with changes in the expression/function of receptors targeted by TKIs, the expression of plasma membrane transporters involved in sorafenib uptake/efflux may affect the response of leukemia cells to this drug.
PMID: 29983874 [PubMed]
Application of next-generation sequencing (NGS) panels is usually limited to diagnosis, prognosis, and development of personalized treatment strategies/targeted therapies for patients with myeloid malignancies e.g., Myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and acute myelogenous leukemia (AML). Here we present a case of 3 year old male that presented with pancytopenia and splenomegaly. His initial bone marrow revealed mild to moderate fibrosis (normocellular; no increase in blasts).
B-ALL is the most common pediatric malignancy, accounting for ∼25% of cancers before 15 years of age. It represents a heterogeneous disease with morphologically identical leukemic cells seemingly arising from different biological mechanisms. Initial workup and evaluation of B-ALL has become increasingly complex partly due to the genetic abnormalities that ar e targets for specific therapy and play an important role in monitoring residual disease. Clinical management and risk stratification depend largely on the results of chromosomal abnormalities obtained using conventional cytogenetics and FISH testing, and a testing…
Chromosome analysis and FISH demonstrate that ploidy changes, particularly gains in ploidy, are common in many tumors. However, with DNA copy number microarray or sequencing, all ploidy information is relative rather than exact. In this context, accurate ploidy assessment is based on software algorithms and the user’s experience in analysis of the data; FISH or karyotype information can serve in a supportive role for challenging cases. In rare cases of near-haploid genomes, it is more common for the predominant clone to be the doubling of the haploid line, as is the case for near-haploid acute lymphoblastic leukemia.
T-cell acute lymphoblastic leukemia (T-ALL) represents a rare hematologic malignancy with poor outcomes in both children and adults. This leukemia typically features a primary abnormality that provides maturation arrest, in addition to secondary abnormalities associated with proliferation and cell survival. The wide-ranging scale of these genomic abnormalities requires multiple technical approaches, from classical karyotyping to chromosomal microarray and molecular sequencing, which confounds and may preclude complete characterization of T-ALLs.
Background: Whole genome high density (HD) SNP microarray analysis provides valuable insights into the cancer genome, unveiling important prognostic findings and therapeutic targets.
B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. Genomic alterations in B-ALL are essential for disease diagnosis, prognosis, and treatment. We performed integrated genomic analysis on 136 pediatric B-ALL patients using the CHOP Comprehensive Hematological Cancer NGS Panel along with conventional cytogenetic studies. The panel interrogates 118 cancer genes for sequence and copy number variants (CNV) and 110 genes for known and novel fusions. Clinically significant genomic changes were identified in 89.7% of patients.
Acute myeloid leukemia (AML) is grouped in multiple subtypes based on recurrent genomic abnormalities with diagnostic and prognostic significance. To enhance our diagnostic approach, we developed a clinical whole-genome mate pair-sequencing (MPseq) assay to detect structural rearrangements and copy number changes. DNA is processed using Illumina Nextera MP library kit, sequenced and aligned to the reference genome using BIMA. Abnormalities are visualized using Mayo-developed Ingenium software using AML-panel restricting analysis to classic-AML rearrangements: ABL1, BCR, CBFB, CREBBP, DEK, KAT6A, MECOM, MLF1, MLL(KMT2A), MY…